title: Evaluation of intralesional injection of verapamil in treatment of Peyronie's disease.
abstract: OBJECTIVE
  To evaluate the effect of intralesional injection of verapamil in Peyronie's plaque with confirmed lesion.
  
  
  METHODS
  This randomized clinical trial was carried out between March 2005 and March 2006 on 16 patients with Peyronie's disease who were referred to the Urology Clinic of Shohadaye Ashayer Hospital in Khorram Abad, Iran. Performing a comprehensive physical exam, the genitalia of the patients were checked to confirm the diagnosis and reject other sexual disorders. Besides, parameters such as penis curving, lesion size were measured. Then, based on the 10-point visual analogue scale, sexual satisfaction of patients and their wives were recorded in a questionnaire. Patients got intralesional verapamil every 14 days and were treated for 6 months. After that, the parameters were assessed and data collected was analyzed using paired t-test. P-value < 0.05 was considered statistically significant.
  
  
  RESULTS
  On average, lesion size and penis curving decreased 30%. Almost 20% of patients and their wives were satisfied with the outcome of the treatment. No significant side effect was seen during the treatment.
  
  
  CONCLUSIONS
  Injection of calcium channel blockers are effective for treatment of the Peyronie's disease; however, more studies with more patients are needed
authors.affiliation: Shohadaye Ashayer Hospital, Lorestan University of Medical Sciences, Lorestan, Islamic Republic of Iran.
authors.forename: Mohammad
authors.initials: M
authors.lastname: Heidari
authors.forename: Jahanbakhsh Reza
authors.initials: JR
authors.lastname: Nejadi
authors.forename: Ahmad
authors.initials: A
authors.lastname: Ghate
authors.forename: Bahram
authors.initials: B
authors.lastname: Delfan
authors.forename: Elham
authors.initials: E
authors.lastname: Iran-Pour
mesh_terms: D000328:Adult; D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D010411:Penile Induration / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D014665:Vasodilator Agents; D014700:Verapamil